Pathogenic mobile element insertion in the MEN1 gene mimicking a deletion in MLPA: characterisation by long-read sequencing Authors: Aleksandra Pfeifer, Jadwiga Zebracka-Gala, Agnieszka Pawlaczek, Artur Zajkowicz, Agata Abramowicz, Karolina Tecza, Agnieszka Kotecka-Blicharz, Hanna Langer-Maciol, Marta Cieslicka, Dagmara Rusinek, Malgorzata Porc, Renata Cyplinska, Malgorzata Oczko-Wojciechowska Published: 2026 ABSTRACT AbstractBackgroundMobile element insertions (MEIs) disrupting coding sequences are rare but clinically significant mutations that are often missed by standard next-generation sequencing (NGS) workflows. Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant tumour predisposition syndrome caused by pathogenic variants in the MEN1 gene.MethodsPatients included in this study were referred for genetic testing of hereditary cancer syndromes. In a validation of our NGS-based copy number variant detection pipeline, four cases showed discrepancies between NGS and multiplex ligation-dependent probe amplification (MLPA) results. Further investigation using soft-clipped read analysis and the MEI detection tool Scramble revealed an Alu insertion in the MEN1 gene. Long-read whole genome sequencing (LR-WGS) was used for validation and complete characterisation of the variant. Additionally, 2014 retrospective NGS samples were analysed with Scramble. Relatives of probands were tested with MLPA and PCR. Positive samples were analysed with Sanger sequencing.ResultsThe apparent exon 2 deletion detected by MLPA was shown to be a false positive caused by an Alu insertion within the probe binding site. LR-WGS confirmed the pathogenic variant (MEN1:c.143_144insAlu) and resolved its complete sequence. Screening of the retrospective cohort revealed no additional MEIs. Altogether, we identified 10 affected individuals from two Polish families carrying hereditary MEN1:c.143_144insAlu, which segregates with MEN1 syndrome.ConclusionWe report a novel pathogenic Alu insertion in the MEN1 gene, which is associated with MEN1 syndrome. Our findings underscore the importance of incorporating MEI detection into routine diagnostics. It also emphasises the necessity of interpreting single-exon MLPA deletions cautiously, as recommended in the MLPA protocol.Keywords: High-Throughput Nucleotide Sequencing; Mutagenesis, Insertional; Germ-Line Mutation; Loss of Function Mutation; Endocrine Gland Neoplasms WHAT IS ALREADY KNOWN ON THIS TOPIC Mobile element insertions (MEI) account for approximately 0.03–0.04% of hereditary diseases, including hereditary cancer syndromes. Multiple endocrine neoplasia type 1 (MEN1) syndrome is caused by pathogenic variants in the MEN1 gene, and more than 1500 germline mutations in the MEN1 gene have been reported. Mobile element insertions (MEI) account for approximately 0.03–0.04% of hereditary diseases, including hereditary cancer syndromes. Multiple endocrine neoplasia type 1 (MEN1) syndrome is caused by pathogenic variants in the MEN1 gene, and more than 1500 germline mutations in the MEN1 gene have been reported. WHAT THIS STUDY ADDS This study identifies a novel pathogenic variant causing MEN1 syndrome: MEN1:c.143_144insAlu. The insertion can lead to false-positive results in multiplex ligation-dependent probe amplification (MLPA) by mimicking a single-exon deletion in the MEN1 gene. This study identifies a novel pathogenic variant causing MEN1 syndrome: MEN1:c.143_144insAlu. The insertion can lead to false-positive results in multiplex ligation-dependent probe amplification (MLPA) by mimicking a single-exon deletion in the MEN1 gene. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study expands the knowledge of hereditary pathogenic variants in the MEN1 gene and highlights the relevance of MEI detection in diagnostic workflows of hereditary disorders. Furthermore, it emphasises the necessity of cautious interpretation of single-exon deletions detected through MLPA. This study expands the knowledge of hereditary pathogenic variants in the MEN1 gene and highlights the relevance of MEI detection in diagnostic workflows of hereditary disorders. Furthermore, it emphasises the necessity of cautious interpretation of single-exon deletions detected through MLPA. Introduction Transposable elements (TEs) are DNA sequences that have the ability to change their position within a genome.1 Among various types of mobile elements, Alu elements, with more than 1 million copies in the human genome, are the most common.2 They belong to a class of retrotransposons called short interspersed elements and are typically of about 280–300 bp in length.2–4 Although transposition is a natural evolutionary process, the integration of TEs into a regulatory or coding sequence can have serious functional consequences.3 5 The insertion of an Alu element into genic regions can easily introduce a premature termination codon (PTC) or a frameshift, effectively preventing the formation of a functional protein. Mobile element insertions (MEIs) are associated with approximately 0.03–0.04% of cases of human genetic disorders, including hereditary cancer syndromes.6 7 They have been reported in multiple cancer-related genes, such as BRCA2, BRCA1 or ATM.8 A significant example is the Alu insertion in BRCA2 exon 3 (c.156_157insAlu), which represents over one-fourth of deleterious BRCA variants in northern/central Portugal.9 Alu elements may also contribute to disease through another mechanism. Recombination between two similar Alu elements can result in Alu/Alu-mediated rearrangements including genomic structural variations like insertions, deletions or duplications.10 For example, pulmonary arterial hypertension can be caused by the localisation of Alu in the BMPR2 gene leading to non-allelic homologous or non-homologous recombination.11 Multiple endocrine neoplasia type 1 (MEN1; MIM#131100) is an endocrine tumour predisposition syndrome, inherited in an autosomal dominant manner.12 First described by Wermer in 1954 as the familial occurrence of multiple adenomas in endocrine glands,13 MEN1 is a rare syndrome with an established prevalence of approximately 1 in 30 000 individuals in Caucasian populations.14 The main manifestations of MEN1 are parathyroid adenomas (primary hyperparathyroidism, PHPT), duodenopancreatic neuroendocrine tumours and anterior pituitary adenomas (PAs) or, according to the new classification, pituitary neuroendocrine tumours with lifetime incidence rates of 95%, 80% and 50%, respectively. Other features may include thymic, lung and gastric neuroendocrine tumours (NETs), adrenal cortical adenomas, skin lesions, lipomas and meningiomas. Additionally, women with MEN1 syndrome have an increased risk of breast cancer compared with the general population. Patients with MEN1 have a decreased life expectancy compared with the general population, which is mainly due to malignant NETs, particularly duodenopancreatic and thymus NETs.12 MEN1 syndrome is caused by germline variants in the tumour suppressor menin 1 (MEN1) gene, located on the long arm of chromosome 11 (11q13).12 The MEN1 gene has over 1500 germline variants described, but with no known mutational hotspot. It is estimated that about 10% of MEN1 alterations arise de novo in patients with no familial history. Penetrance exceeds 95% by the age of 50; however, there is no clear correlation between specific MEN1 variants and the clinical manifestations of MEN1 syndrome.15 16 To date, only one pathogenic MEI has been reported in MEN1: an Alu insertion in exon 9 (NM_130799.2:c.1430_1431insAlu; ClinVar accession: VCV001772480.2), associated with a hereditary cancer-predisposing syndrome. No other MEIs in MEN1 have been described in the literature or mutation databases. Another pathogenic MEN1 variant related to Alu elements involves an Alu/Alu-mediated deletion of the entire gene, as reported by Yoshiji et al17 and Fukuuchi et al.18 Interestingly, in silico analyses indicate the possible predisposition of the MEN1 gene to Alu retrotransposon-mediated genomic deletion.17 Here, we report a novel pathogenic Alu insertion in exon 2 of the MEN1 gene. This was found in two Polish families with MEN1 syndrome. The insertion was initially detected by targeted next-generation sequencing (NGS). It was then confirmed and fully characterised using long-read whole genome sequencing (LR-WGS). The variant we found mimics a deletion of exon 2 of the MEN1 gene in multiplex ligation-dependent probe amplification (MLPA). Our study shows the benefit of using long-read sequencing for MEI detection and stresses the need to consider MEI detection in genetic testing of hereditary diseases. Materials and methods Sample collection In total, 2028 samples were derived from peripheral blood during routine diagnosis at the Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch (figure 1). All patients were referred for genetic testing for suspected hereditary variants associated with endocrine tumours, Lynch syndrome or breast cancer. Samples were analysed using targeted NGS (2014 samples), MLPA (38 samples) and LR-WGS (three samples), some samples being analysed with more than one method. Sample collection and analysis workflow. CNV, copy number variant; LR-WGS, long-read whole genome sequencing; MEI, mobile element insertion; MLPA, multiplex ligation-dependent probe amplification; NGS, next-generation sequencing; ONT, Oxford Nanopore Technologies. During validation of the NGS-based copy number variant (CNV) detection pipeline, 24 samples previously classified as CNV positive by MLPA were analysed with targeted NGS. The results from both methods were then compared. Four samples showed discordant results between MLPA and NGS. MLPA indicated a deletion in the MEN1 gene, whereas NGS did not detect any deletion. Further analysis of the NGS data revealed that the discrepancy was caused by an MEI interfering with the MLPA probe site. LR-WGS on the Oxford Nanopore platform was subsequently performed for three of these samples to confirm and fully characterise the MEI variant. The four patients originated from two families with MEN1 syndrome. 18 members of the two families were tested for the variant using MLPA and PCR, and positive members were also tested with Sanger sequencing. Furthermore, 2014 previously sequenced samples (Illumina targeted NGS) were reanalysed for MEIs using Scramble software. Written informed consent was obtained from all members (or their caregivers) of the described families for the use of their tissue for analysis. Targeted NGS Genomic DNA was isolated from peripheral blood leucocytes. The NGS reaction was performed using available kits: TruSight Cancer (Illumina, San Diego, California, USA), SeqCap EZ Choice and Kapa HyperExplore (Roche, Basel, Switzerland) or Agilent SureSelect XT HS (Agilent, Santa Clara, California, USA), according to the manufacturer’s instructions. Libraries were sequenced in paired-end mode (2×76 or 2×151 cycles) at a minimum average depth of 20× at the MiniSeq or NextSeq 550DX sequencer. A detailed description of the targeted NGS methods is provided in the online supplemental materials. Long-read whole genome sequencing LR-WGS was performed by genXone (Złotniki, Poland) using the PromethION platform (Oxford Nanopore Technologies (ONT), Oxford, UK) for three selected samples with a discrepancy between MLPA and NGS results. Genomic DNA was extracted from 0.5 mL of blood using the Monarch HMW DNA Extraction Kit for Cells & Blood (New England Biolabs, Ipswich, Massachusetts, Cat No T3050S), according to the manufacturer’s instructions. Sequencing libraries were prepared using the Ligation Sequencing Kit V14 (SQK-LSK114, ONT) and sequenced using PromethION flow cells R10.4.1 (FLO-PRO114, ONT) on a PromethION device (ONT) with MinKNOW V.24.06.15 and super-accurate base call mode. MLPA analysis of MEN1 Analysis of large deletions and duplications of chromosome fragments was performed using the commercial SALSA MLPA Probemix P017 MEN1 kit (MRC-Holland, Amsterdam, The Netherlands), according to the manufacturer’s protocol. A detailed description of the MLPA analysis of MEN1 is provided in the online supplemental materials. PCR and Sanger sequencing Primers were designed using National Center for Biotechnology Information (NCBI) primer (F-MEN1: 5′-CCGACAAAAGAGGGGAAGCC-3′, R-MEN1: 5′-TGGGCTCCAACCTGTGATGA-3′ and F-Alu: 5′-GGACTGCGGACTGCAGTG-3′) (figure 2A). PCR was performed using the primer pair flanking the Alu insertion (F-MEN1 and R-MEN1) or using the primer pair specific for MEN1:c.143_144insAlu (F-Alu and R-MEN1). Sanger sequencing was performed on a 3500xl genetic analyser (Applied Biosystems-Life Technologies, USA). Results of PCR amplification and Sanger sequencing. (A) The genomic sequence of MEN1 exon 2 (and adjacent intronic regions) containing the Alu insertion, shown in antisense orientation relative to the direction of MEN1 transcription. Primer binding sites used for PCR and Sanger sequencing are marked with boxes. (B) PCR products run on a 2% agarose gel. Upper gel: PCR-MEN1 with flanking primers shows an extra band in insertion-positive members. Lower gel: PCR-MEN1-Alu specifically amplifies the Alu-containing allele in positive members only; absent in negatives and negative control. (C) Electropherograms showing sequences of MEN1 exon 2. The upper electropherogram represents a control sample negative for the MEN1:c.143_144insAlu variant. The lower two electropherograms show results from the patient positive for MEN1:c.143_144insAlu. MEN1, multiple endocrine neoplasia type 1. A detailed description of the PCR and Sanger sequencing methods is provided in the online supplemental materials. Analysis of NGS data Raw reads were processed with fastp 0.23.2, then trimmed reads were aligned to the hg38 reference genome with bwa-mem 0.7.17, and duplicated reads were removed by GATK MarkDuplicates 4.3.0.0.19 20 The detection of CNVs was performed using ExomeDepth 1.1.15.21 Additionally, base resolution copy number visualisation was performed using the internal tool, based on the work by Schenkel et al.22 For this purpose, the depth at each base position was calculated using Samtools V.1.15.1, then normalised and visualised using R V.4.1.3.23 24 Copy number analysis was performed separately for each sequencing run. Soft-clipped reads in the analysed region (exon 2 of MEN1 gene) were visually examined using Integrative Genomics Viewer (IGV) software. Then they were queried using the Basic Local Alignment Search Tool (BLASTN) algorithm against the human reference genome, with repeat masking disabled. Finally, NGS data were analysed using Scramble 1.0.2 tool, which detects MEIs based on clusters of soft-clipped reads in BAM files.6 Analysis of LR-WGS data The reads were aligned using Minimap2 V.2.28 to the human reference genome hg38.25 The variants were called using the epi2me-labs/wf-human-variation workflow (v.2.7.2), which uses Sniffles2 v.2.6.3 for the detection of structural variants and snpEff 5.1d for the annotation of variants.26 27 To classify the sequence inserted into the MEN1 gene, we compared it with sequences from the open database of repetitive DNA elements Dfam v3.8.28 Visualisation of sequencing reads and detected variants was performed using the IGV.29 Cosegregation analysis The cosegregation of the variant with the disease was examined using the method proposed by Jarvik and Browning.30 Given that a distant relationship between Families 1 and 2 cannot be fully excluded, a conservative approach was taken, following the criteria recommended for a single family. Two individuals with only one MEN1-related manifestation were conservatively counted together as a single informative meiosis in the analysis to avoid overestimating cosegregation strength. Results Detection of Alu insertion During the validation of the NGS-based CNV detection method, we compared the results of NGS and MLPA analyses and found discrepancies in four samples (figure 1). Specifically, MLPA indicated a deletion of exon 2 in the MEN1 gene (figure 3A). But the NGS did not detect any deletion, either by exomeDepth or visual inspection of normalised read depth plots (figure 3B). Further visual examination of NGS reads in IGV showed multiple soft-clipped reads with identical soft-clipped sequences (figure 3C). BLASTN analysis of these soft-clipped sequences revealed high similarity to the 5’ end of the Alu sequence. It suggested that an Alu insertion exists in the MEN1 gene. To verify this finding, we reanalysed the NGS data of these samples using software designed explicitly for MEI detection (Scramble). The software confirmed the presence of the Alu insertion in exon 2 of the MEN1 gene. Applying Scramble to the entire 2014 NGS cohort revealed no other MEIs in the remaining samples. MLPA, targeted NGS and LR-WGS results for the MEN1:c.143_144insAlu-positive sample. (A) MLPA indicates a false deletion of exon 2. (B) Normalised copy number plot (21 samples) for the MEN1 gene. Value 1 indicates neutral copy number (two copies), 1.5 indicates one copy gain and 0.5 indicates one copy loss. The plot shows no CNVs in the MLPA-positive sample or other samples from the run. (C) Read alignments from NGS and LR-WGS. CNV, copy number variant; LR-WGS, long-read whole genome sequencing; MLPA, multiplex ligation-dependent probe amplification; NGS, next-generation sequencing; ONT, Oxford Nanopore Technologies. Overall, we detected an Alu insertion in four of 2014 samples (0.2%). These four samples originated from two families with MEN1 syndrome. To investigate the discrepancy between the MLPA and NGS results, we compared the Alu insertion site with the location of the MLPA probe. We found that the Alu insertion site was located within the hybridisation region of the MLPA probe. The insertion likely prevented probe hybridisation, resulting in a false-positive MLPA result in exon 2 of the MEN1 gene. Validation and characterisation of the Alu insertion using LR-WGS To validate the Alu insertion detected in the MEN1 gene, we performed LR-WGS in three out of four samples harbouring this variant (figure 3C). Sequencing produced an average read length of 14.6–17.2 kb with a mean coverage of 27–32× in each sample. In all three cases, the analysis confirmed a heterozygous Alu insertion in exon 2 of the MEN1 gene. Long-read sequencing enabled the complete characterisation of the inserted element. The detailed Human Genome Variation Society (HGVS) notation of the detected variant is as follows: NM_001370259.2:c.143_144insTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCCAGGCCGGACTGCGGACTGCAGTGGCGCAATCTCGGCTCACTGCAAGCTCCGCTTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGCGCCCGCCACCGCGCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCTTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCATGATCCACCCGCCTCGGCCACCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCGGCCTCGTGGAGCATTTTCT. For clarity throughout this manuscript, we refer to the variant in its simplified form as MEN1:c.143_144insAlu. The insertion is located in exon 2, p.Leu48 of MEN1 (NM_001370259.2), between chr11:64,809,966 and chr11:64,809,967 of the hg38 genome (figure 4). The inserted sequence is composed of a complementary inverted AluYb8 element and a target site duplication (TSD). The length of polyA in Alu is approximately 44 nucleotides; however, its exact length remains unknown due to the limitations of long-read sequencing.31 The TSD sequence (TCGTGGAGCATTTTCT) represents a copy of the sequence NM_001370259.2:c.128–143 (chr11:64,809,967–64,809,982). Given the uncertainty in polyA length, we considered all three reading frames, assuming polyA stretches of 44, 45 and 46 nucleotides. In each case, the insertion introduces a premature stop codon: NM_001370259.2:p.(Leu48_Ala49ins*15), NM_001370259.2:p.(Leu48_Ala49ins*72) or NM_001370259.2:p.(Leu48_Ala49ins*55). All 19 alternative MEN1 transcripts present in the RefSeq database are predicted to be affected. According to the SnpEff annotation, the variant results in nonsense-mediated mRNA decay (NMD) and loss of function. We classified this variant as pathogenic according to the American College of Medical Genetics (ACMG) 2015 criteria.32 We based our classification of the variant on three pieces of evidence demonstrating its pathogenicity. The variant in question causes a frameshift, resulting in the premature appearance of a translation termination codon, which is very strong evidence of pathogenicity (PVS1). Additionally, the detected variant is absent from gnomAD and ClinVar databases, which fulfils the criterion of low population frequency (PM2). The conclusive evidence of the variant’s pathogenicity is the cosegregation with MEN1 syndrome in affected families (PP1) (described in the next section). Detailed characterisation and visualisation of the NM_001370259.2(MEN1):c.143_144insAlu variant. (A) The Alu insertion occurs in MEN1 at p.Leu48, between c.143 and c.144. The AluYb8 element is inserted into the coding sequence in an inverted complementary orientation and is accompanied by target site duplication (TSD) of the sequence TCGTGGAGCATTTTCT (MEN1:c.128–143). (B) The sequence of exon 2 of the MEN1 gene (NM_001370259.2) with AluYb8 insertion. A white background indicates the wild-type MEN1 exon 2 sequence, with untranslated region (UTR) marked by a dotted underscore. A grey background highlights the insertion sequence, which includes inverted complementary AluYb8 (in bold) and TSD (single underscored). The double underscore within the AluYb8 sequence indicates a mismatch relative to the reference AluYb8 sequence from the Dfam database. The exact length of polyT stretch in the insertion is unknown due to the limitations of long-read sequencing technology. Validation of the Alu insertion using PCR and Sanger sequencing All 18 family members were tested for the MEN1:c.143_144insAlu variant using PCR. 10 individuals tested positive, while eight tested negative (figure 2A). All carriers were heterozygous for the variant (figure 2B). Sanger sequencing of all PCR-positive samples confirmed the expected insertion sequence in each case (figure 2C). The PCR results aligned with the MLPA findings, which had indirectly suggested the presence of the MEN1:c.143_144insAlu variant. Familial segregation of the variant We detected the described MEN1 variant in two families. To improve clarity, the first family is presented as two subfamilies. The proband of the first subfamily is related to the proband of the second subfamily as a cousin of the father. However, the exact details of their shared ancestry remain unclear. Families 1 and 2 are not closely related, with no first-degree or second-degree relationships identified; however, a more distant familial relationship cannot be excluded. In the first subfamily (figure 5, Family 1a), the male proband (I-1) was diagnosed in the sixth decade of life with a functioning (adrenocorticotropic hormone (ACTH) ectopy) pancreatic neuroendocrine neoplasm with metastatic spread; the histological diagnosis was established by mediastinal lymph node biopsy. Concomitantly, PHPT was diagnosed, and subtotal parathyroidectomy revealed parathyroid gland hyperplasia. Later, diagnostic procedures revealed a functioning PA producing growth hormone, which was treated with transsphenoidal surgery, followed by long-acting somatostatin receptor analogue therapy due to persistent IGF-1 excess. Two offspring of the proband were tested for the MEN1 variant: a son (II-1) in his fourth decade and a daughter (II-2) in her third decade. Only the daughter was a carrier of the pathogenic variant. She had PHPT and a clinically non-functioning PA identified at the time of genetic testing. Unilateral parathyroidectomy was performed at initial diagnosis, with recurrence of hypercalcaemia 10 years after the primary surgery. The PA remains stable under surveillance. Genetic testing was also performed on the proband’s brother (I-3), with a negative result. Pedigrees of reported families with MEN1 syndrome. Subfamilies 1a and 1b are related. However, the exact details of their shared ancestry remain unclear. dec, decade of life at diagnosis; LR-WGS, long-read whole genome sequencing; MEN1, multiple endocrine neoplasia type 1; MLPA, multiplex ligation-dependent probe amplification; NGS, next-generation sequencing; PA, pituitary adenoma; PHPT, primary hyperparathyroidism; pNEN, pancreatic neuroendocrine neoplasm. In the second subfamily (figure 5, Family 1b), there was one male proband (I-3), who was diagnosed with a clinically non-functioning PA, pancreatic neuroendocrine tumour (pNET) and hyperparathyroidism in his fourth decade of life. Histopathological analysis of the excised parathyroid gland confirmed a parathyroid adenoma. Due to the clinical appearance of pNET, distal pancreatectomy with splenectomy was performed, confirming a multifocal G2 neuroendocrine neoplasm. Proband’s brother (I-1), after revealing the pathogenic variant of MEN1 in the fifth decade of life, was simultaneously diagnosed with a clinically non-functioning PA, a functioning (insulinoma) pNET and PHPT. He was treated with subtotal parathyroidectomy, and histological examination revealed parathyroid hyperplasia. pNET with metastatic spread was treated with a long-acting somatostatin analogue and diazoxide, with histological diagnosis set on biopsy of liver metastasis. The proband has two sons (II-3 and II-4) in the first and second decades of life with a confirmed pathogenic variant of MEN1, without phenotypic occurrence of MEN1 syndrome so far. In two sons of the proband’s brother (II-1 and II-2), MEN1 gene analysis did not reveal the presence of any pathogenic variants. In the second family (figure 5, Family 2), we identified two probands, two sisters. The first sister (I-3) was diagnosed in the seventh decade of life with pNET and hyperparathyroidism. PHPT persisted after excision of a single parathyroid gland. pNET was treated with a long-acting somatostatin analogue. The second sister (I-5) was diagnosed in her sixth decade of life with pancreatic neuroendocrine neoplasm with liver metastases. Histology was obtained from a pancreatic tumour biopsy. We performed MEN1 gene analysis on five offspring: three from the first sister and two from the second. We confirmed the pathogenic MEN1 variant in the daughter (II-3) of the first proband, diagnosed in her third decade of life with concomitant hyperparathyroidism, and in the son (II-1), diagnosed in his fifth decade of life with hyperparathyroidism and pancreatic neuroendocrine neoplasm. DNA analysis was also performed on the probands’ brother (I-1) with a negative result. A total of 18 patients from two families were tested for the germline MEN1:c.143_144insAlu variant, and 10 of them harboured the variant. Eight out of 10 variant carriers exhibited symptoms of MEN1 syndrome, while the two youngest carriers, in their first and second decades of life, were asymptomatic. Among the affected carriers, hyperparathyroidism was observed in seven, pancreatic neuroendocrine neoplasms in six and PAs in four. None of the negative patients had symptoms of MEN1 syndrome. In the cosegregation analysis, the probability that the variant cosegregates with the disease by chance was calculated as 1/16. This result provides moderate evidence for cosegregation and can be applied as moderate evidence in ACMG classification, according to Jarvik and Browning.30 Discussion Here we present the second reported case with MEN1 syndrome caused by an Alu insertion in the coding sequence: MEN1:c.143_144insAlu. This novel variant cosegregates with MEN1 syndrome in two Polish families and is predicted to be pathogenic. It was initially detected in targeted NGS data and subsequently validated and fully characterised using LR-WGS, PCR and Sanger sequencing. The insertion also caused a false-positive result in the MLPA assay. Among the 10 carriers, eight were symptomatic. At the same time, the two youngest males (in their first and second decades of life) had not yet developed clinical features of MEN1, which is consistent with the estimated disease penetrance of 7% at age 10 and 52% at age 20.33 Among the eight symptomatic carriers, seven (88%) had hyperparathyroidism, six (75%) had pancreatic neoplasms and four (50%) had PAs, which align with the reported lifetime prevalence of 95%, 80% and 50%, respectively.12 Overall, these findings indicate that the clinical expression of the variant is consistent with the typical MEN1 phenotype. In silico analysis revealed that the MEN1:c.143_144insAlu leads to the premature appearance of a stop codon in the MEN1 gene. Such variants typically result in the complete loss of translated protein due to NMD or the formation of a shorter form of the menin protein.15 PTC variants are a well-established pathogenic mechanism in MEN1, with approximately 69% of MEN1 alterations reported to introduce a PTC, most commonly through nonsense or frameshift variants and less frequently via splicing alterations or large deletions.14 16 The MEN1:c.143_144insAlu variant is expected to result either in NMD or in the production of a truncated protein retaining only the N-terminal 8% of the wild-type protein. Consequently, all nuclear localisation signals, located between amino acids 479 and 610 (cyt), would be lost.34 35 The variant would also be expected to disrupt interactions between menin and its multiple protein partners.36 According to the ClinVar database (accessed 15 February 2026), 119 frameshift or nonsense variants have been reported in exon 2 of MEN1 (NM_001370259.2), of which 117/119 (98%) are classified as pathogenic or likely pathogenic. Since MEN1 syndrome is a genetic disorder inherited in an autosomal dominant manner with a serious outcome leading to a reduction in life expectancy and quality, the early diagnosis of patients and their family members is crucial for proper monitoring and identification of early-stage lesions. Immediate treatment increases the likelihood of limiting the disease’s effects and improves survival.37 Our research contributes to the development and improvement of diagnostics for patients with MEN1 syndrome, increasing their chances of receiving appropriate care. Our findings also highlight the importance of incorporating the detection of rare variant types into routine germline testing. Pathogenic germline variants include single-nucleotide variants or small indels as well as rare CNVs and extremely rare MEIs. Including them in diagnostic pipelines increases the yield of targeted NGS. Although in routine genetic diagnostics, MLPA is the gold standard method for determining exon-level rearrangements, the study emphasises the importance of carefully interpreting MLPA results. In samples harbouring MEI in MEN1, we obtained a false-positive MLPA finding. This observation highlights a known pitfall of the method, acknowledged by the manufacturer.38 MLPA is a relatively simple, sensitive and cost-effective method and is widely used for detecting large genomic rearrangements. However, it is crucial to be aware of its limitations and interpret the results with caution, and to implement verification procedures using direct sequencing, additional MLPA kits and/or resampling.39–41 False positives in MLPA can arise due to multiple factors, both sample-related and technical mechanisms. Probe hybridisation and ligation can be affected by polymorphisms, secondary structure formation at binding sites, mosaicism, as well as insertions of Alu or Long Interspersed Nuclear Elements (LINE).42 Several reports have described cases of false-positive results in different genes (including DMD, BRCA1 and BRCA2), all of which emphasise the need to confirm MLPA results using an alternative method.41 43 44 Lau et al reported an Alu element insertion in SLC25A13 that caused a false-positive MLPA signal—a mechanism similar to what we observed in MEN1.45 Although false-positive MLPA results may arise from variants (single nucleotide variants, indels or MEIs) in the probe hybridisation region, a normal copy number in MLPA does not exclude the presence of pathogenic exonic variants. It is also worth noting that a small but clinically relevant subset of patients with MEN1 are reported as MEN1 mutation negative despite fulfilling diagnostic criteria. This raises the question of whether such individuals are truly negative or whether they carry pathogenic alterations not captured by routine testing—for example, deep intronic variants, complex structural rearrangements, low-level mosaicism or insertional events that escape detection or disrupt probe performance.46–48 Therefore, improving the sensitivity of molecular diagnostics to detect non-canonical or structurally complex variants remains essential. This highlights the value of NGS-based approaches capable of identifying atypical events, such as the Alu insertion observed in our cohort. Lastly, the present study did not include functional assays, such as assessment of mutant allele expression or loss of heterozygosity in tumour tissue. This was primarily due to the study design and scope, which focused on characterising the MEN1 variant at the genetic predisposition level rather than evaluating its biological effects. Additionally, limited access to tumour tissue—available for only one patient—restricted such analyses. While blood samples were collected from all patients, MEN1 expression in peripheral blood would not provide a meaningful proxy for expression patterns in endocrine tumours, given the tissue-specific nature of MEN1 regulation. Despite the absence of tumour-based functional studies, the variant meets ACMG classification criteria for pathogenicity. In summary, we identified a novel MEN1:c.143_144insAlu variant that cosegregates with MEN1 syndrome in two families and is predicted to be pathogenic based on in silico analyses. This finding expands the spectrum of hereditary MEN1 variants and underscores the need to incorporate MEI detection into diagnostic pipelines. It also highlights the importance of carefully interpreting single-exon deletions detected by MLPA. Our study further demonstrates the value of long-read sequencing in characterising MEI insertions. Supplementary material Footnotes Funding: The research was financed by an internal grant (SN/MGW12/2024) from the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants and was approved by the Bioethics Committee of the Maria Sklodowska-Curie National Research Institute of Oncology (opinion number 11/2024) in Warsaw. Participants (or their caregivers) gave informed consent to participate in the studies for scientific purposes, including genetic research. Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. References Associated Data Supplementary Materials Data Availability Statement All data relevant to the study are included in the article or uploaded as supplementary information.